Overview
EVAN HELPS EMERGING COMPANIES EXECUTE STRATEGIC FINANCING AND M&A TRANSACTIONS SO THEY CAN TAKE THEIR BUSINESS TO THE NEXT LEVEL.
Evan has substantial experience representing public and private life science and technology companies across a broad range of matters that include venture capital and private equity financings, initial public offerings, mergers and acquisitions and strategic technology transactions.
In addition to maintaining an active specialty practice focused on the life science industry, Evan frequently advises underwriters on public offerings and private equity sponsors in the negotiation and execution of buyout transactions. Evan also advises U.S. companies and investors with respect to operations and investments in China, and is fluent in Cantonese and Mandarin.
Evan is Co-Chair of the firm's life sciences and healthcare practice and leads Dorsey’s Corporate practice in Northern California. Evan is a member of the firm’s Management Committee and oversees the firm's strategic growth.
Education & Admissions
University of Virginia School of Law (J.D., 2001), Articles Review Board Member, Virginia Journal of Law and Technology
Georgia Institute of Technology (B.S., Computer Engineering, 1998), graduated with highest honors
Admissions
- California
- District of Columbia
Languages
- Fluent in Cantonese and Mandarin
Experience
Representative Experience
- Adiana in its acquisition by Cytyc
- Advanced Stent Technologies in its acquisition by Boston Scientific
- Applied Imaging in its acquisition by Genetix
- Global Post Ventures in its leveraged acquisition of Pacific Title & Art Studio from Safeguard Scientifics
- Occam Networks in its acquisition of Accelerated Networks
- Thermage in its initial public offering
- TogetherSoft in its acquisition by Borland
Evan has represented many investment banking clients in public offering transactions, including Citigroup, Cowen, HSBC, Lazard, and Merrill Lynch. Please find below a list of selected representations of Emerging Growth Companies:
- 3ware (funded by U.S. Venture Partners, VantagePoint Venture Partners, and others)
- Acclarent (funded by New Enterprise Associates, Versant Ventures, and others)
- Arkal Medical (funded by MedVenture Associates and Delphi Ventures)
- DFine (funded by Prospect Venture Partners and Vanguard Ventures)
- Diligent Software Systems (funded by Battery Ventures and Concord Ventures, and others)
- eFinance (funded by Sprout Group, NIF Ventures, and others)
- Endocyte (funded by Burrill & Company, Sanderling Ventures, and others)
- Fluid Medical (funded by ITX International)
- ForteBio (funded by Alloy Ventures, Vertical Group, and others)
- Metrika (funded by Oak Hill Venture Partners, Sutter Hill ventures, Three Arch Partners, and others)
- NeoTract (funded by New Enterprise Associates)
- NovoVascular (funded by Asset Management Company)
- Otismed Corporation (funded by Kleiner Perkins Caufield & Byers)
- PolyRemedy (funded by MedVenture Associates)
- Revascular Therapeutics (funded by Latterell Venture Partners, and others)
- Rojo Networks (funded by Texas Pacific Group Ventures)
Industries & Practices
Energy & Natural Resources
Explore This Practice View client achievements related to this practice View resources related to this practiceHealthcare & Life Sciences
Explore This Practice View client achievements related to this practice View resources related to this practice- Capital Markets
- China
- Emerging Companies
- Energy & Natural Resources
- Healthcare & Life Sciences
- Mergers & Acquisitions
- Video Games
